病理学家主导的非小细胞肺癌生物标志物检测：实施的基本原理和考虑因素的专家共识。
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
机构信息
Department of Cellular Pathology, Royal Liverpool University Hospital, Liverpool, UK.
Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Ciberonc and Complutense University, Madrid, Spain.
出版信息
ESMO Open. 2023 Aug;8(4):101587. doi: 10.1016/j.esmoop.2023.101587. Epub 2023 Jun 23.
Abstract
Biomarker tests in lung cancer have been traditionally ordered by the treating oncologist upon confirmation of an appropriate pathological diagnosis. The delay this introduces prolongs yet further what is already a complex, multi-stage, pre-treatment pathway and delays the start of first-line systemic treatment, which is crucially informed by the results of such analysis. Reflex testing, in which the responsibility for testing for an agreed range of biomarkers lies with the pathologist, has been shown to standardise and expedite the process. Twelve experts discussed the rationale and considerations for implementing reflex testing as standard clinical practice.
摘要
生物标志物检测在肺癌中的应用一直以来都是在病理诊断确认后由治疗肿瘤学家进行的。这种方法引入的延迟进一步延长了本已复杂的、多阶段的治疗前途径，并延迟了一线系统治疗的开始，而这一治疗的关键是基于此类分析的结果。基于病理学家的职责进行一系列约定生物标志物检测的反射性检测已经显示出标准化和加速这一过程的效果。十二位专家讨论了将反射性检测作为标准临床实践的实施的基本原理和考虑因素。
相似文献
1
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.病理学家主导的非小细胞肺癌生物标志物检测：实施的基本原理和考虑因素的专家共识。
ESMO Open. 2023 Aug;8(4):101587. doi: 10.1016/j.esmoop.2023.101587. Epub 2023 Jun 23.
2
Response to letter entitled: letter comments on: Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.对题为《关于非小细胞肺癌生物标志物的病理学家启动的反射检测的信件评论：实施原理与考量的专家共识》的信件的回复
ESMO Open. 2023 Oct;8(5):101828. doi: 10.1016/j.esmoop.2023.101828. Epub 2023 Oct 10.
3
Consensus recommendations for optimizing biomarker testing to identify and treat advanced mutated non-small-cell lung cancer.优化生物标志物检测以识别和治疗晚期突变型非小细胞肺癌的共识建议。
Curr Oncol. 2020 Dec;27(6):321-329. doi: 10.3747/co.27.7297. Epub 2020 Dec 1.
4
Impact of Reflex EGFR/ ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.晚期非鳞状非小细胞肺癌患者接受治疗的时间受 EGFR/ALK 检测的影响。
J Oncol Pract. 2017 Feb;13(2):e130-e138. doi: 10.1200/JOP.2016.014019. Epub 2016 Dec 28.
5
A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.系统评价和加拿大共识建议：生物标志物在非小细胞肺癌治疗中的应用。
J Thorac Oncol. 2011 Aug;6(8):1379-91. doi: 10.1097/JTO.0b013e318220cb8e.
6
Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma.肺腺癌中针对分子生物标志物的反射性检测的临床实用性。
Clin Lung Cancer. 2020 Sep;21(5):437-442. doi: 10.1016/j.cllc.2020.05.007. Epub 2020 May 13.
7
Benefits of Implementing Reflex Genomic Analysis for Nonsmall Cell Lung Cancer.实施反射基因组分析对非小细胞肺癌的益处。
J Appl Lab Med. 2024 Jan 3;9(1):28-40. doi: 10.1093/jalm/jfad104.
8
[When to Test in Biomarker-stratified Therapy of Non-small Cell Lung Cancer - Biomarker-stratified Therapy of Non-small Cell Lung Cancer: When and What to Test?].[非小细胞肺癌生物标志物分层治疗中的检测时机——非小细胞肺癌生物标志物分层治疗：何时检测及检测什么？]
Pneumologie. 2021 Sep;75(9):641-643. doi: 10.1055/a-1486-9057. Epub 2021 Sep 15.
9
Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer.生物标志物检测与晚期非小细胞肺癌患者的治疗决策时间。
Ann Oncol. 2015 Jul;26(7):1415-21. doi: 10.1093/annonc/mdv208. Epub 2015 Apr 28.
10
A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study.西班牙关于早期表皮生长因子受体突变型非小细胞肺癌（NSCLC）临床管理的德尔菲共识小组：一项德尔菲共识小组研究。
Clin Transl Oncol. 2023 Jan;25(1):283-291. doi: 10.1007/s12094-022-02941-5. Epub 2022 Sep 27.
引用本文的文献
1
Expert recommendations for biomarker evaluation of advanced non-small cell lung cancer in Thailand.泰国晚期非小细胞肺癌生物标志物评估的专家建议。
Transl Lung Cancer Res. 2025 Jul 31;14(7):2387-2402. doi: 10.21037/tlcr-2025-201. Epub 2025 Jul 28.
2
Access to treatment-guiding biomarkers in the UK: surveys of cancer patients and healthcare professionals.英国治疗指导生物标志物的获取：癌症患者与医疗保健专业人员调查
Future Oncol. 2025 Aug;21(20):2625-2636. doi: 10.1080/14796694.2025.2535098. Epub 2025 Aug 8.
3
Novel Approach to Proficiency Testing Reveals Significant Variations in Biomarker Practice Leading to Critical Differences in Lung Cancer Management.能力验证的新方法揭示了生物标志物应用中的显著差异，这些差异导致肺癌管理出现关键区别。
JTO Clin Res Rep. 2025 Apr 22;6(7):100837. doi: 10.1016/j.jtocrr.2025.100837. eCollection 2025 Jul.
4
Recommendations for diagnosis and management of non-small-cell lung carcinoma patients with ex20ins EGFR mutations: insights from a Delphi consensus.具有外显子20插入型表皮生长因子受体（EGFR）突变的非小细胞肺癌患者的诊断和管理建议：德尔菲共识的见解
Clin Transl Oncol. 2025 Jun 19. doi: 10.1007/s12094-025-03971-5.
5
Optimization of oncology biomarker testing in managed care: Best practices and consensus recommendations from an AMCP Market Insights program.管理式医疗中肿瘤生物标志物检测的优化：AMCP市场洞察项目的最佳实践与共识建议
J Manag Care Spec Pharm. 2025 Jun;31(6-a Suppl):S1-S14. doi: 10.18553/jmcp.2025.31.6-a.s1.
6
Prevalence of gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study.西班牙早期可切除非小细胞肺癌患者的基因突变患病率：ORIGEN研究
Transl Lung Cancer Res. 2025 Apr 30;14(4):1254-1265. doi: 10.21037/tlcr-2024-1146. Epub 2025 Apr 21.
7
Emerging molecular testing paradigms in non-small cell lung cancer management-current perspectives and recommendations.非小细胞肺癌治疗中新兴的分子检测模式——当前观点与建议
Oncologist. 2025 Mar 10;30(3). doi: 10.1093/oncolo/oyae357.
8
Implementation of the clinical practice of liquid biopsies for thoracic oncology the experience of the RespirERA university hospital institute (Nice, France).胸科肿瘤液体活检临床实践的实施：法国尼斯RespirERA大学医院研究所的经验
J Liq Biopsy. 2023 Aug 16;1:100004. doi: 10.1016/j.jlb.2023.100004. eCollection 2023 Sep.
9
Results of a modified Delphi consensus on the optimal testing pathway for oesophago-gastric cancer care in the UK.英国食管癌和胃癌护理最佳检测途径的改良德尔菲共识结果。
BMJ Open. 2025 Feb 6;15(2):e094343. doi: 10.1136/bmjopen-2024-094343.
10
Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario Forum.早期非小细胞肺癌（NSCLC）的实用管理最新进展：安大略论坛报告。
Curr Oncol. 2024 Nov 8;31(11):6979-6999. doi: 10.3390/curroncol31110514.
本文引用的文献
1
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.癌基因成瘾性转移性非小细胞肺癌：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2023 Apr;34(4):339-357. doi: 10.1016/j.annonc.2022.12.009. Epub 2023 Jan 23.
2
Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan.日本肺癌患者下一代测序诊断生物标志物检测的真实世界研究。
Cancer Sci. 2023 Jun;114(6):2524-2533. doi: 10.1111/cas.15752. Epub 2023 Mar 2.
3
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.辅助奥希替尼治疗 EGFR 突变型 IB-IIIA 期非小细胞肺癌：III 期随机 ADAURA 试验的更新结果。
J Clin Oncol. 2023 Apr 1;41(10):1830-1840. doi: 10.1200/JCO.22.02186. Epub 2023 Jan 31.
4
Expert opinion on NSCLC small specimen biomarker testing - Part 1: Tissue collection and management.非小细胞肺癌小标本生物标志物检测专家意见——第 1 部分：组织采集和管理。
Virchows Arch. 2022 Sep;481(3):335-350. doi: 10.1007/s00428-022-03343-2. Epub 2022 Jul 20.
5
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.伴有驱动基因改变的IV期非小细胞肺癌的治疗：美国临床肿瘤学会生存指南
J Clin Oncol. 2022 Oct 1;40(28):3310-3322. doi: 10.1200/JCO.22.00824. Epub 2022 Jul 11.
6
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.ESMO 专家共识声明：表皮生长因子受体突变型非小细胞肺癌的管理。
Ann Oncol. 2022 May;33(5):466-487. doi: 10.1016/j.annonc.2022.02.003. Epub 2022 Feb 14.
7
Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model.使用决策分析模型比较下一代测序与单基因检测在检测转移性非小细胞肺癌基因组改变中的经济影响
JCO Precis Oncol. 2019 Dec;3:1-9. doi: 10.1200/PO.18.00356.
8
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.Ⅰ-Ⅲ期非小细胞肺癌的分子检测：方法与挑战。
Lung Cancer. 2021 Dec;162:42-53. doi: 10.1016/j.lungcan.2021.09.003. Epub 2021 Sep 15.
9
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.欧洲非小细胞肺癌生物标志物检测的发展态势
Lung Cancer. 2021 Apr;154:161-175. doi: 10.1016/j.lungcan.2021.02.026. Epub 2021 Feb 22.
10
Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?临床实践中的下一代测序：它是单基因检测方法的一种节省成本的替代方案吗？
Pharmacoecon Open. 2021 Jun;5(2):285-298. doi: 10.1007/s41669-020-00249-0. Epub 2021 Mar 4.
Zotero 插件